CN
Search...
About Us
Group Overview
Management Team
Milestones of Chipscreen
Group Honors
Social Responsibility
Core Technologies and R&D
Core Technologies
Scientific Committee
R&D System
Drug Lifecycle Management
Pipeline
Pipelines
News & Events
Company News
Media Coverage
Notices & Announcements
Video Library
Investors
Company Announcements
Periodic Reports
Career Development
Contact Us
Contact Details
CN
EN
News & Events
Chipscreen Highlights: Stay Updated on Recent Hot Topics
Home
News & Events
Company News
Media Coverage
Notices & Announcements
Video Library
Select year
2026
2025
2024
2023
2022
Earlier
shown/page
5
5
10
15
20
2025.03.11
AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
Full text
2024.11.18
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Full text
2024.10.17
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Full text
2024.10.15
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Full text
2024.07.23
NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment
NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment
Full text
05
06
07
...
24
Media contact
（+86）0755-36993500
pr@juliucq.com
